SRA737, the Sareum originated Chk1 inhibitor which is the subject of the Company’s first licensing deal, has had data released from the ongoing monotherapy and low dose gemcitabine (LDG) trials by Sareum’s licensing partner Sierra Oncology, Inc. (Nasdaq:SRRA), in two poster presentations at the 2019 Annual Meeting of the American Society of Clinical Oncology. We believe the results and implications for further clinical development significantly de-risk the program and accelerates
04 Jun 2019
SRA737 trial results substantially derisk asset – safety and preliminary efficacy in multiple cancer indications – warrants registration intended P2 trial in anogenital cancer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SRA737 trial results substantially derisk asset – safety and preliminary efficacy in multiple cancer indications – warrants registration intended P2 trial in anogenital cancer
Sareum Holdings plc (SAR:LON) | 10.8 0 0.0% | Mkt Cap: 7.71m
- Published:
04 Jun 2019 -
Author:
Derren Nathan -
Pages:
9
SRA737, the Sareum originated Chk1 inhibitor which is the subject of the Company’s first licensing deal, has had data released from the ongoing monotherapy and low dose gemcitabine (LDG) trials by Sareum’s licensing partner Sierra Oncology, Inc. (Nasdaq:SRRA), in two poster presentations at the 2019 Annual Meeting of the American Society of Clinical Oncology. We believe the results and implications for further clinical development significantly de-risk the program and accelerates